concentra - Search News

Acelyrin, Concentra

Concentra Offers to Buy Acelyrin, Endangering Proposed Merger With Alumis

Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding the combined company over until 2027.

Seeking Alpha on MSN · 2d

Acelyrin jumps 11% on acquisition offer from Concentra Biosciences

Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash payment of $3.00 per share, along with a contingent value right (CVR) that entitles shareholders to 80% of the net proceeds from any future out-licensing or sale of Acelyrin's development

MarketWatch · 1d

Acelyrin Stock Jumps on Concentra Acquisition Interest

Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in premarket trading. Shares had fallen 31% year to date when the market closed Thursday.

Business Insider · 2d

Acelyrin confirms unsolicited indication of interest from Concentra Biosciences

Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP

FierceBiotech1d

Concentra curveball offer throws Acelyrin merger with Alumis into doubt

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

ENDPOINTS NEWS1d

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...

TipRanks on MSN1d

Select Medical Faces Financial Risks Amid Separation Agreement with Concentra

Select Medical (SEM) has disclosed a new risk, in the Litigation & Legal Liabilities category. Select Medical may face significant business risks ...

Jim Cramer on Concentra Group Holdings Parent, Inc. (CON): ‘I Think This One’s Worth Putting On Your Shopping List’

We recently published an article titled Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a ...

Nasdaq1mon

Concentra (CON) Upgraded to Strong Buy: Here's What You Should Know

Concentra Group (CON) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject ...

Activist investor threatens Peninsula drug maker's merger plans

Here's how an activist investor is threatening a Peninsula drug maker's merger plans. And the drama introduces a potential ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results